Edwards Lifesciences (EW) Tops Q1 EPS by 10c; Issues Mixed Outlook

Edwards Lifesciences (NYSE: EW) reported Q1 EPS of $1.22, $0.10 better than the analyst estimate of $1.12. Revenue for the quarter came in at $938 million versus the consensus estimate of $932.25 million.

GUIDANCE:

Edwards Lifesciences sees FY2018 EPS of $4.50-$4.70, versus the consensus of $4.54.

Edwards Lifesciences sees FY2018 EPS of $1.05-$1.15, versus the consensus of $1.17.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins
• Playboy to buy back 16.6M shares from Fortress at $1.05 each